Drug Profile

CWT 001

Alternative Names: CWT-001; TenoMiR™

Latest Information Update: 06 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Causeway Therapeutics
Class MicroRNAs
Mechanism of Action Collagen modulators; MicroRNA modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Tennis elbow
Phase I Peyronie's disease

Most Recent Events

10 Apr 2024 Phase-II clinical trials in Tennis elbow in United Kingdom (Intralesional) (NCT06192927)
10 Jan 2024 Causeway Therapeutics plans a phase II trial for Tennis elbow (Intralesional, Injection) in January 2024 (NCT06192927)
03 Oct 2023 CWT 001 is still in phase I trials for Tendon injuries (In adults, In the elderly) in United Kingdom (Intralesional) (Causeway Therapeutics pipeline, October 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com